NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Takeda
City of Hope Medical Center
City of Hope Medical Center
Alaunos Therapeutics
Tempus AI
Incyte Corporation
Day One Biopharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc.
Sichuan Enray Pharmaceutical Sciences Company
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
Pfizer
NGM Biopharmaceuticals, Inc
Elevation Oncology
Intensity Therapeutics, Inc.
Alliance for Clinical Trials in Oncology
BerGenBio ASA
Merck Sharp & Dohme LLC
Stanford University
Novartis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NantCell, Inc.
NantCell, Inc.
Pfizer
ADC Therapeutics S.A.
Weill Medical College of Cornell University
Exelixis
Eli Lilly and Company
Pfizer
Pfizer
Massachusetts General Hospital
Rutgers, The State University of New Jersey
pharmaand GmbH
Hoffmann-La Roche
Genmab
Revolution Medicines, Inc.
Montefiore Medical Center
Five Prime Therapeutics, Inc.
Hackensack Meridian Health
Gilead Sciences
Bristol-Myers Squibb
University of Chicago
Gilead Sciences
National Institutes of Health Clinical Center (CC)
Stanford University
Icahn School of Medicine at Mount Sinai
National Institutes of Health Clinical Center (CC)
Pfizer
Pharmacyclics LLC.